Specifically, results from the randomized phase III trial showed that maintenance therapy with olaparib (Lynparza) was found to significantly improve progression-free survival (PFS) versus placebo in patients with germline BRCA-positive metastatic pancreatic cancer. Read more . . .
The POLO trial demonstrated that maintenance therapy with a PARP inhibitor can be beneficial for patients with BRCA-positive metastatic pancreatic cancer, thus underscoring the need to screen these patients for molecular abnormalities so that they can be paired with the most effective treatment possible, said Donald A. Richards, MD, PhD.